Barclays analyst Luke Sergott maintains Repligen (NASDAQ:RGEN) with a Overweight and raises the p

On October 06, 2026, Repligen Corp (RGEN) shares experienced a notable decline of 7.7%, bringing the

WALTHAM, Mass., Oct. 06, 2026 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ: RGEN, “Repligen”, or

On October 05, 2026, Repligen Corp (RGEN) shares rose 4.3%, bringing the current price to $189.50. T

BioLife Solutions NASDAQ: BLFS stockholders approved the company's merger agreement with Repligen Co

Repligen Corporation (NASDAQ: RGEN - Get Free Report) reached a new 52-week high on Wednesday. The s

This whale alert can help traders discover the next big trading opportunities. Whales are entities w

Tidal Investments LLC increased its stake in shares of Repligen Corporation (NASDAQ: RGEN) by 75.2%

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr.,

Repligen Corporation (RGEN) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript

UBS analyst Dan Leonard maintains Repligen (NASDAQ:RGEN) with a Buy and raises the price target f

Repligen (RGEN) reported earnings 30 days ago. What's next for the stock?

Halozyme, Repligen, Iovance, Arcutis and Precigen have been highlighted in this Industry Outlook art

American Capital Management Inc. acquired a new position in shares of Repligen Corporation (NASDAQ:

New drug approvals and encouraging pipeline progress should maintain momentum in the Zacks Biomedica

WALTHAM, Mass., Aug. 26, 2026 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life science

Bank of Nova Scotia acquired a new stake in Repligen Corporation (NASDAQ: RGEN) during the second qu

On August 19, 2026, Merck (NYSE:MRK | MRK Price Prediction) and Moderna (NASDAQ:MRNA) announced posi

B. Metzler seel. Sohn and Co. AG acquired a new position in shares of Repligen Corporation (NASDAQ:

Avidity Partners Management LP increased its position in shares of Repligen Corporation (NASDAQ: RGE

The consensus price target hints at a 25.7% upside potential for Repligen (RGEN). While empirical re

Wells Fargo analyst Evan Stampler maintains Repligen (NASDAQ:RGEN) with a Overweight and raises t

JP Morgan analyst Casey Woodring maintains Repligen (NASDAQ:RGEN) with a Overweight and raises th

RGEN tops Q2 earnings and revenue estimates, lifts its 2026 revenue and EPS outlook, and sees shares

Repligen Corporation (RGEN) Q2 2026 Earnings Call Transcript

A deepening chip rout drags the Nasdaq while Coca-Cola and Sherwin-Williams beats power the Dow; oil

Gainers OPKO Health (NASDAQ:OPK) shares increased by 34.7% to $1.67 during Tuesday's regular se

U.S. stocks mixed, Dow Jones up 300 points. Shares of Sherwin-Williams rose 7.8% after reporting bet

Repligen (NASDAQ:RGEN) reported quarterly earnings of $0.54 per share which beat the analyst consens

Repligen (NASDAQ:RGEN) raises FY2026 Adj EPS guidance from $1.97-$2.05 to $2.03-$2.09 vs $2.00 analy

Repligen to acquire BioLife Solutions for $1.5B to boost cell therapy bioprocessing capabilities and

BioLife stockholders will receive $11.25 per share in cash and 0.1442 shares of Repligen common stoc

Semiconductors led a broad rebound Tuesday as Micron, Western Digital and Sandisk surged. Nasdaq 100

Benchmark analyst Robert Wasserman upgrades Repligen (NASDAQ:RGEN) from Hold to Buy and announces

Evercore ISI Group analyst Daniel Markowitz maintains Repligen (NASDAQ:RGEN) with a Outperform an

HSBC analyst Sidharth Sahoo maintains Repligen (NASDAQ:RGEN) with a Buy and lowers the price targ

Wolfe Research analyst Mike Polark assumes Repligen (NASDAQ:RGEN) with a Outperform rating and an

RBC Capital analyst Dan Leonard reinstates Repligen (NASDAQ:RGEN) with a Outperform and announces

JP Morgan analyst Casey Woodring maintains Repligen (NASDAQ:RGEN) with a Overweight and lowers th

Barclays analyst Luke Sergott maintains Repligen (NASDAQ:RGEN) with a Overweight and raises the p

CURRENT GUIDANCE (at May 5, 2026) FY 2026Adjusted (non-GAAP)Total Reported Revenue$803M - $833MRepor

FINANCIAL GUIDANCE FOR FULL YEAR 2026All adjusted figures are non-GAAPOur financial guidance for the

Repligen (NASDAQ:RGEN) reported quarterly earnings of $0.48 per share which beat the analyst consens

Canaccord Genuity analyst Kyle Mikson maintains Repligen (NASDAQ:RGEN) with a Hold and lowers the

Roth Capital analyst Natalya Davies initiates coverage on Repligen (NASDAQ:RGEN) with a Buy ratin

Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology lead

Evercore ISI Group analyst Daniel Markowitz maintains Repligen (NASDAQ:RGEN) with a Outperform an

HC Wainwright & Co. analyst Raghuram Selvaraju maintains Repligen (NASDAQ:RGEN) with a Buy an

UBS analyst Dan Leonard maintains Repligen (NASDAQ:RGEN) with a Buy and lowers the price target f